RayzeBio: Funding, Investors & Team (Sep 2026)
RayzeBio is focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. As the emerging leader in radiopharmaceuticals, RayzeBio is developing an innovative robust pipeline against validated oncology drug targets to deliver radioisotopes that emit alpha particles such as Actinium-225.
RayzeBio has raised $373M across 3 funding rounds on record, the most recent a Series D of $160M announced in Sep 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
RayzeBio Company Profile and Key Stats
Latest funding round on record: Sep 2022.
RayzeBio Funding Rounds
RayzeBio raised $105M in an undisclosed round announced in Dec 2020.
6 months later, an undisclosed round of $108M was announced in Jun 2021.
1.3 years later, a Series D of $160M was announced in Sep 2022.
RayzeBio Founders and Leadership Team
Contact details for the RayzeBio team: 1 of 2 have an email address on file.
Start 14-day free trial →RayzeBio Funding Compared to Other Biotechnology Startups
RayzeBio's latest round of $160M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like RayzeBio in Biotechnology and San Diego
Companies Similar to RayzeBio
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
RayzeBio Funding FAQs
What does RayzeBio do?
RayzeBio is focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. As the emerging leader in radiopharmaceuticals, RayzeBio is developing an innovative robust pipeline against validated oncology drug targets to deliver radioisotopes that emit alpha particles such as Actinium-225.
How much funding has RayzeBio raised?
RayzeBio has raised $373M across 3 rounds on record. The most recent is a Series D of $160M announced in Sep 2022.
When did RayzeBio last raise funding?
RayzeBio's most recent funding round on record is a Series D of $160M, announced in Sep 2022.
Who founded RayzeBio?
FundedIQ lists Deborah Charych (Founder) at RayzeBio.
Who is the CEO of RayzeBio?
Ken Song is listed as CEO at RayzeBio.
Where is RayzeBio headquartered?
RayzeBio is based in San Diego, California, United States.
How many employees does RayzeBio have?
RayzeBio is in the 101-250 employee band.
How does RayzeBio's funding compare to other Biotechnology startups?
RayzeBio's latest round of $160M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's RayzeBio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for RayzeBio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.